Bivalirudin: a new generation antithrombotic drug

Bibliography

• BATES SM, WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. J. Cardiol (1998) 82 (8B):12P–18P.
   Google Scholar
• MARAGANORE JM, BOURDON P, JABLONSKI J, RAMACHANDRAN KL, FENTON JVV 2ND: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry (1990) 29(307095–7101.
   Web of Science ®Google Scholar
• ••A fundamental synthesis and SAR study on hirudinderivatives.
   Google Scholar
• PARRY MA, MARAGANORE JM, STONE SRN: Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry (1994) 33 (49):14807–14814
   PubMed Web of Science ®Google Scholar
• WITTING JI, BOURDON P, BREZNIAK DV, MARAGANORE JM, FENTON JW, 2ND: Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem. J. (1992) 283\(Pt. 3)737–743.
   Google Scholar
• RUBENS FD, WEITZ JI, BRASH JL, KINLOUGH-RATHBONE RL: The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thromb. HaemosL (1993) 69(2):130–134.
   PubMed Web of Science ®Google Scholar
• SHEN GX, REN S, FENTON JVV: Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells. Semin. Thromb. HaemosL (1998) 24(2):151–156.
   PubMed Web of Science ®Google Scholar
• KELLY AB, MARAGANORE JM, BOURDON P, HANSON SR, HARKER LA: Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc. Natl. Acad. Sci. USA (19 9 2) 89(13)6040–6044.
   Google Scholar
• JACKSON MR, REID TJ, TANG DB, O'DONNELL SD, GOMEZ ER, ALVING BM: Antithrombotic effects of hirulog in a rat carotid endarterectomy model. J. Surg. Res. (1996) 60(1):15–22.
   PubMed Web of Science ®Google Scholar
• HAMELINK JK, TANG DB, BARR CF et al.: Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J. Vasc. Surg. (1995) 21 (3):492–498.
   PubMed Web of Science ®Google Scholar
• FOX I, DAWSON A, LOYNDS P et al.: Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb. HaemosL (1993) 69(2):157–163.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MARAGANORE JM, LOSCALZO J et al.: Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am. J. Cardiol (1993) 71(10):778–782.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, BONAN R, JEWITT D et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation (1 9 9 3) 87(5):1622–1629.
   Google Scholar
• LIDON RM, THEROUX P, JUNEAU M, ADELMAN B, MARAGANORE J: Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagu-lant, antithrombotic and clinical effects. Circulation (1993) 88(Pt. 01495–1501.
   Google Scholar
• SHARMA GV, LAPSLEY D, VITA JA et al.: Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am. J. Cardiol. (1993) 72(18)1357–1360.
   Google Scholar
• LIDON RM, THEROUX P, LESPERANCE J et al.: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptoki-nase in acute myocardial infarction. Circulation (1994) 89(4) :1567–1572.
   PubMed Web of Science ®Google Scholar
• THEROUX P, PEREZ-VILLA F, WATERS D, LESPERANCE J,SHABANI F, BONAN R: Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocar-dial infarction. Circulation (1995) 91(8)2132–2139.
   Google Scholar
• GINSBERG JS, NURMOHAMED MT, GENT M et al.: Use ofHirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation (1994) 90(5)2385–2388.
   Google Scholar
• GINSBERG JS, NURMOHAMED MT, GENT M et al. Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb. HaemosL (1994) 72(4):523–525.
   PubMed Web of Science ®Google Scholar
• SCATENA R: Bivalirudin. Curr. Opin. Cardiovasc. Pulm. Ren. Drugs (1999) 1:168–183.
   Google Scholar
• BITTL JA, STRONY J, BRINKER JA et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postin-farction angina. Hirulog Angioplasty Study Investiga-tors. N Engl. J. Med. (1995) 333(12):764–769.
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial: Hirulog Angioplasty Study. Results ofthe thrombin inhibition by bivalirudin in coronary angioplasty.
   Google Scholar
• BITTL JA: Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am. Heart J. (1995) 130(3 Pt. 2):658–665.
   Google Scholar
• SHAH PB, AHMED WH, GANZ P, BITTL JA: Bivalirudincompared with heparin during coronary angioplasty for thrombus-containing lesions. J. Am. Coll. Cardiol. (1997) 30(5):1264–1269.
   PubMed Web of Science ®Google Scholar
• BURCHENAL JE, MARKS DS, TIFT MANN J et al. Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am. J. Cardiol. (1998) 82(4):511–555.
   Google Scholar
• BITTL JA, FEIT F: A randomized comparison of bivali-rudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am. J. Cardiol. (1998) 82 (8B):43P–49P.
   Google Scholar
• FUCHS J, CANNON CP: Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIIVID 7 trial. Circulation (1995) 92 (4) :727–733.
   Google Scholar
• ••Phase III clinical trial: Timi 7 Trial. Results of the thrombininhibition by bivalirudin in unstable angina.
   Google Scholar
• WHITE HD, AYLWARD PE, FREY MJ et al.: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfu-sion/Occlusion (HERO) Trial Investigators. Circulation (1997) 96(7):2155–2161.
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial: Hirulog Early Reperfusion/Occlusion(HERO) Trial. Results of the thrombin inhibition by bivali-rudin in thrombolytic therapy.
   Google Scholar
• PINA I: FDA panel votes against approval for bivali-rudin. Circulation (1999) 99 (10):1277.
   PubMed Web of Science ®Google Scholar
• BATES SM, WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. J. Cardiol (1998) 82 (8B) :12P–18P.
   Google Scholar
• WHITE HD: Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. Am. J. Cardiol. (1998) 82 (8B):57P–62P.
   Google Scholar
• TOPOL EJ: Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Am. J. Cardiol (1998) 82 (8B):63P–68P.
   Google Scholar
• FENTON JW 2ND, OFOSU FA, BREZNIAK DV, HASSOUNA HI: Thrombin and antithrombotics. Semin. Thromb. HaemosL (1998) 24(2):87–91.
   PubMed Web of Science ®Google Scholar
• KONG DF, TOPOL EJ, BITTL JA et al.: Clinical outcomes of bivalirudin for ischemic heart disease. Circulation (1999) 100(20)2049–2053.
   Google Scholar